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Abstract The L subunit of human Ca2+/calmodulin-dependent
protein kinase II (L CaMKII) was identified by searching
through an expressed sequence tag database and rapid amplifi-
cation of cDNA 5P-ends and was assigned to chromosome 7.
Reverse transcription-polymerase chain reaction and sequencing
analysis identified at least five alternative splicing variants of
L CaMKII (L, L6, Le, LPe, and L7) in brain and two of them (L6
and L7) were first detected in any species. When expressed in
HEK 293 cells, the Ca2+/calmodulin-dependent kinase activity of
L7, the shortest variant, was much lower than that of either
L (the longest one) or Le (the medium one), suggesting possible
regulation of LCaMKII activity by alternative splicing. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Ca2/calmodulin-dependent protein kinase II (CaMKII), as
a major intracellular mediator of calcium action, regulates a
broad array of functions, especially in long-term potentiation
and neurotransmitter release [1^8]. In mammalian cells, CaM-
KII has four subunits : K, L, Q and N [2]. A critical neuronal
function of the K subunit of CaMKII (K CaMKII) has been
clearly demonstrated by studying mice that were either lacking
K CaMKII or expressed mutated K CaMKII [3^8]. In contrast
to K CaMKII, much less is known about L CaMKII though it
is also a prominent kinase in the central nervous system. Even
up to now, except its partial cDNA sequence [9], the full-
length of human L CaMKII cDNA has not been reported yet.
It is known that CaMKII isozymes are encoded as single
polypeptides, each containing a catalytic, a regulatory, and an
association domain [10]. These three domains are highly con-
served in evolution. A variable region, composed of the di¡er-
ent alternative spliced insertion, has been found between the
calmodulin binding site in the regulatory domain and the
association domain. The functional implications of the varia-
ble region in CaMKII remain largely unknown except that
these variable inserts could in£uence the cellular localization
of the kinase and its interaction with calmodulin [11,12]. This
study thus was undertaken to identify the full coding sequence
of human L CaMKII and its alternative splicing variants.
2. Materials and methods
2.1. cDNA cloning of human L CaMKII and its splicing variants
The expressed sequence tag (EST) database of GenBank was
searched with the mouse CaMKIIL (GenBank accession number
X63615) as probe by Basic local alignment search tool (BLAST)
[13] at the website (http://www.ncbi.nlm.nih.gov) of the National Cen-
ter for Biotechnology Information (NCBI). The 5P rapid ampli¢cation
of cDNA ends (5P RACE) [14] was performed using the human brain
Marathon cDNA library (Clontech) with two gene speci¢c primers
(5P-CCCCATTTGGTGACAATGGAGA-3P and 5P-GTTCTCCGGC-
TTGAGGTCTCT-3P) according to the manufacturer’s protocol. PCR
bands obtained were gel puri¢ed and ligated into pGEM-T vector
(Promega) by TA cloning. Reverse transcription-polymerase chain
reaction (RT-PCR), using the primer pairs: 5P-GCCATGGCCAC-
CACGGTGA-3P and 5P-GAGGCAGACACAAACATGCGA-3P,
was then used to clone the full-length cDNA of human L CaMKII.
With enzymatic digestion, some inserts with di¡erent length were
found, and at least ¢ve variants of human L CaMKII were later
identi¢ed by DNA sequencing. The presence of these variants in
mRNA was con¢rmed by RT-PCR analysis with primers: the sense
(5P-GTCTGCCAACGCTCCACGGTAG-3P) and the antisense (5P-
CGTGAGCCGGATGTAAGCGATGC-3P). The chromosomal local-
ization and the intron^exon mapping of L CaMKII were carried out
by bioinformatics with search in the NCBI sequence tagged site (STS)
database [15].
2.2. Expression and cellular localization of human L CaMKII variants
Human L CaMKII variants were subcloned into pcDNA3 contain-
ing the coding sequence for hemagglutinin (HA) epitope or green
£uorescence protein (GFP) at the amino acid terminus. Indicated
plasmids were transiently transfected into HEK293 cells using calcium
phosphate^DNA coprecipitation method as described [16]. After
transfected with GFP-tagged L CaMKII variant plasmids, the cells
were ¢xed with 4% polyformaldehyde in phosphate-bu¡ered saline
(PBS). Images of subcellular localization of the L CaMKII variants
were recorded by using a Leica TCSNT laser confocal scanning mi-
croscope [17].
2.3. Kinase activity of L CaMKII variants
Kinase activity of CaMKII was determined as previously described
[18]. HEK293 cells, 48 h after transfection with HA-tagged L CaMKII
variants, were lysed and subjected to Western blot analysis and CaM-
KII activity assay. Expression of L CaMKII variants was monitored
by Western analysis. Ca2/calmodulin-dependent or independent ki-
nase activity was measured using speci¢c peptide substrate autocam-
tide-2 (synthesized by Genemed Synthesis) [19]. All reactions were
initiated by addition of 20 Wg of cell extracts containing a comparable
amount of L CaMKII variants and incubated at 30‡C for 30 s. Phos-
phorylation was terminated by spotting an equal amount of sample
onto p81 phosphocellulose paper and immediately immersing into 75
mM H3PO4. Then the radioactivity of samples was quanti¢ed by liq-
uid scintillation counting.
3. Results
3.1. Cloning of human L CaMKII and its splicing variants
By searching against the non-redundant EST database of
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GenBank, we identi¢ed a group of human ESTs, whose de-
duced amino acid sequence was highly homologous to mouse
CaMKIIL (X63615). The contig analysis showed that these
ESTs constructed human L CaMKII but its 5P sequence was
unknown (Fig. 1A). 5P RACE was then performed to obtain
the full-length coding sequence of this kinase, and the product
of 5P RACE (Fig. 1B) was cloned and sequenced. The ATG
start codon of human L CaMKII was deduced according to
the mouse’s. RT-PCR analysis further con¢rmed the presence
of full-length L CaMKII mRNA in human brain (Fig. 1C).
During identi¢cation of L CaMKII clones, some inserts
with di¡erent length were found after enzymatic digestion.
At least ¢ve variants of human L CaMKII were later identi-
¢ed by DNA sequence analysis (L : AF078803, LPe:
AF081572, Le: AF083417, L6: AF081924, L7: AF140350).
Two of these variants were novel and designed as CaMKIIL6
and CaMKIIL7. Further RT-PCR analysis revealed the pres-
ence of L, LPe, and L7 mRNA in brain tissue, LPe and L7
mRNA in SH-SY5Y neuroblastoma cells, and LPe mRNA in
SK-N-SH neuroblastoma and HEK293 cells (Fig. 2A). In
contrast, mRNA of Le or L6 was not detected probably due
to their lower expression levels in the samples tested. It is
interesting to point out that no expression of CaMKIIL was
detected in two kinds of neuroblastoma cells although it was
expressed abundantly in brain.
3.2. Structure of the variable region of the L subunit of human
CaMKII
The analysis of the sequence revealed that these variants
encode proteins with molecular masses from 49 to 60 kDa.
Multiple amino acid sequence alignment of these human var-
iants and mouse CaMKIIL clearly indicated that there are
seven potential variable domains (V1^V7) in the variable re-
gion (Fig. 2B). CaMKIIL7, a novel splicing variant found in
Fig. 1. Cloning of the L subunit of human CaMKII. A: Clones ob-
tained from the EST Database, 5P RACE and RT-PCR. Products
from 5P RACE (B) and RT-PCR (C) were subjected to agarose gel
electrophoresis. The molecular size marker and sample were loaded
in lane 1 and 2 respectively.
Fig. 2. Expression and alignment of the variable region of the hu-
man L CaMKII variants. A: RT-PCR products of samples were an-
alyzed on 9% non-denatured PAGE after enzymatic digestion as
compared to PCR products from positive clones. The expected sizes
of the digested fragment are indicated on the left side in base pairs.
B: Amino acid sequence alignment of the variable region of human
L CaMKII variants with the mouse CaMKIIL. The dashed lines in-
dicate the absence of the alternative spliced insertions. The di¡erent
amino acids between mouse CaMKIIL and human L CaMKII are
marked in gray.
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this study, lacks V2 and V5 domains which has been previ-
ously reported as invariable ‘tether’ domains [9]. CaMKIIL6,
another novel variant, is the ¢rst reported isoform lacking the
variable domain V7.
To further test if these variants are really derived from
alternative splicing, the genomic DNA sequence of variable
region of L CaMKII was analyzed by bioinformatics. One
human DNA contig NT-002349 assigned to human chromo-
some 7 was identi¢ed, which contains all of the L CaMKII
gene except its 5P end. Examination of the variable region
between the calmodulin binding site and the association do-
main showed that seven potential exons (V1^V7) identi¢ed by
the above protein sequence analysis map well with the rule of
the intron^exon junction (data not shown). These seven exons
were all £anked by the canonical consensus splice donor and
acceptor sites: AG at the 3P splice site and GT at the 5P splice
site [20]. This indicated that ¢ve L CaMKII variants identi¢ed
in this study are indeed derived from the alternative.
3.3. Cellular localization of CaMKII variants
To investigate the relationship between structure and cellu-
lar localization of these L CaMKII variants, three of them
(the longest one: CaMKIIL, the medium one: CaMKIILe
and the shortest and novel one: CaMKIIL7) were fused
with GFP. Previous study has shown that the GFP tag does
not a¡ect L CaMKII’s activity to phosphorylate the peptide
substrate and its cellular localization [21]. When expressed in
HEK293 cells, all these three variants of L CaMKII distrib-
uted primarily in the cytosol and no signi¢cant di¡erence in
cellular distribution was observed (Fig. 3). In contrast, cells
expressing GFP alone showed homogeneous green £uores-
cence both in the nucleus and in the cytosol.
3.4. The kinase activity of L CaMKII variants
HA-tagged CaMKIIL, CaMKIILe, and CaMKIIL7 were
transiently expressed in HEK293 cells, and the level of their
expression was detected by Western blot analysis using anti-
HA monoclonal antibody (Fig. 4A). The results showed that
expressed variants possess di¡erent apparent molecular
masses from 47 to 60 kDa, which is similar with those pre-
dicted based on their amino acid sequences. The peptide au-
tocamtide-2, a CaMKII speci¢c substrate [19], was used as
peptide substrate to investigate the kinase activity of three
variants. As shown in Fig. 4B, in the absence of Ca2/calmod-
ulin all three variants did not display signi¢cant basal kinase
activity towards the peptide autocamtide-2. In the presence of
Ca2/calmodulin, however, CaMKIIL and CaMKIILe sub-
stantially phosphorylated the peptide substrate whereas CaM-
KIIL7 did not exhibit signi¢cant kinase activity under the
same conditions (Fig. 4B).
4. Discussion
Though it is a prominent kinase in the central nervous
system, much less is known about L CaMKII as compared
with K CaMKII. In this study, at least ¢ve variants of
L CaMKII, likely derived from alternative splicing, are ob-
tained from brain tissue. It has been shown that the variable
region of murine L CaMKII is encoded by four exons [22].
But our results indicate that at least seven exons encode the
human L CaMKII variable region, which may thus produce
more splicing alternatives. This suggests that variable region
Fig. 3. Cellular localization of the human L CaMKII variants. GFP
(A), GFP-tagged CaMKIIL (B), GFP-tagged CaMKIILe (C), and
GFP-tagged CaMKIIL7 (D) were transiently transfected into
HEK293. Images were recorded by using a laser confocal scanning
microscope after ¢xing with 4% polyformaldehyde in PBS.
Fig. 4. Kinase activity of human L CaMKII splicing variants. A:
Western blot analysis of expression of HA-tagged L CaMKII in
HEK293 by anti-HA antibody. B: Ca2/calmodulin dependent or
independent kinase activity of the variants was measured using spe-
ci¢c peptide substrate autocamide-2. Results are expressed as
mean þ S.D. of three independent experiments.
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of L CaMKII evolves quickly and also implies that the region
plays an important role in the function of L CaMKII.
It is very likely that the pattern of the alternative splicing
may be related with the type of tissues and cells, developmen-
tal status, and physiological and pathological conditions. For
instance, CaMKIILPe is shown to be expressed not only in
brain tissue and two types of neuroblastoma cells but also
in non-neural cells such as HEK293 cells, THP-1 cells (data
not shown) and likely in mammary tumor cells [9]. In con-
trast, CaMKIIL is abundantly expressed in the brain tissue
but is not detected in the two types of neural cells tested in
this study. Furthermore, CaMKIIL7 is detected only in SH-
SY5Y cells but not in SK-N-SH cells, indicating the di¡erent
alternative splicing pattern even between di¡erent neuroblas-
toma cell lines. Interestingly, our data suggest that expression
of CaMKIILPe may be functionally related to cell prolifera-
tion since it is detected in both neuroblastoma cells and em-
bryonic cells.
It has been shown that the ‘tether’ domains in the variable
region, composed of V2 and V5 domains, are present in every
splicing variant of all four isoforms of CaMKII [9]. It is also
proposed that the N-terminus of the ‘tether’ domain may
modify Ca2/calmodulin binding a⁄nity or substrate speci¢c-
ity while its C-terminus may regulate the multimeric size of
the kinase [12,23]. But in one of the two novel splicing var-
iants (CaMKIIL7) identi¢ed in this study, the ‘tether’ domains
appear to be deleted which is further con¢rmed by ¢nding a
corresponding EST (AA399393) in GenBank. Consequently,
the deletion of ‘tether’ domains may thus lead to the loss of
kinase activity in vitro as tested in this study. However, it
remains unclear why this inactive variant is expressed in brain
and how its expression is regulated? It could also not be
excluded that this splicing variant may possess other than ki-
nase functions such as a targeting module to localize other
members of CaMKII to synaptic and cytoskeletal sites of
action [24].
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